Dossier assessment
Glecaprevir/pibrentasvir (acute hepatitis C) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Glecaprevir/pibrentasvir (acute hepatitis C) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Glecaprevir/pibrentasvir (acute hepatitis C) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Acute hepatitis C virus infection in adults and children aged 3 years and older
Added benefit not proven
Project details
- Project no.
- A26-92
- Commission
- Commission awarded on 20.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-92
Connected Projects
-
Dossier assessment
Glecaprevir/pibrentasvir (chronic hepatitis C) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed